Abstract

Thrombolysis by intravenous recombinant tissue plasminogen activator (rt-PA) is an effective therapy in acute ischemic stroke (AIS). Thrombin generation test (TGT) is a global hemostasis test providing information about the speed and amount of generated thrombin in plasma. Here we aimed to find out whether results of this test before the initiation of thrombolysis might predict outcomes. Study population included 120 consecutive AIS patients, all within 4.5 hours of their symptom onset, who underwent thrombolysis by rt-PA. Blood samples were collected from all patients upon admission and TGT was performed using platelet poor plasma. Clinical data of patients including the NIHSS were registered at admission, day 1 and 7 after therapy. The ASPECT score was assessed using CT images taken before and 24 hours after thrombolysis. Long-term functional outcome was defined 3 months after the event by the modified Rankin Scale. Endogenous Thrombin Potential (ETP) and Peak Thrombin were significantly lower in patients with cardioembolic IS. Symptomatic intracranial hemorrhage (SICH) was found in 6 patients and was significantly associated with low ETP and Peak Thrombin levels. A multiple logistic regression model revealed that an ETP result in the lower quartile is an independent predictor of mortality within the first two weeks (OR: 6.03; 95%CI: 1.2–30.16, p<0.05) and three months after the event (OR: 5.28; 95%CI: 1.27–21.86, p<0.05). Low levels of ETP and Peak Thrombin parameters increase the risk of therapy associated SICH. A low ETP result is an independent predictor of short- and long-term mortality following thrombolysis.

Highlights

  • Intravenous administration of recombinant tissue plasminogen activator has been proven to be an effective therapy for acute ischemic stroke (AIS) [1,2]

  • A total of 120 consecutive AIS patients receiving i.v. thrombolysis were included in the study

  • In this single-center study of 120 AIS patients treated with i.v. t-PA, we show for the first time that results of the thrombin generation test obtained before the thrombolytic treatment could be a useful marker to predict short- and long-term outcomes

Read more

Summary

Introduction

Intravenous administration of recombinant tissue plasminogen activator (rt-PA) has been proven to be an effective therapy for acute ischemic stroke (AIS) [1,2]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call